TMRW Life Sciences is a technology company.
TMRW Life Sciences has raised $138.0M across 2 funding rounds.
TMRW Life Sciences has raised $138.0M in total across 2 funding rounds.
TMRW Life Sciences has raised $138.0M in total across 2 funding rounds.
TMRW Life Sciences's investors include Vasudev Bailey, Highland Capital Partners, Hoxton Ventures, Pieter Kemps, Questa Capital, Radical Ventures, The House Fund, What If Ventures, Michael Baum, AngelList, Cyberstarts VC, DST Global.
TMRW Life Sciences is a fertility technology company founded in 2017 and headquartered in New York, specializing in the world's first FDA-cleared automated platform for managing and storing frozen eggs and embryos in IVF labs.[1][4] It serves fertility clinics and patients by addressing critical risks in manual cryostorage—such as specimen mix-ups, damage, or loss—through robotics, RFID tracking, intuitive software (ivfOS), remote monitoring, and a complete digital chain of custody, reducing potential points of failure by 94% and optimizing lab workflows.[1][2][4][5] Named Fast Company's #1 Most Innovative Biotech Company in 2022, TMRW has gained adoption by leading U.S. clinics and is expanding into the UK and Europe, with state-of-the-art onsite and offsite biorepositories offering liquid or vapor storage options.[1][2][4]
TMRW Life Sciences emerged from the need to modernize outdated manual processes in IVF labs, where frozen specimens are handled for years amid rising demand for fertility treatments.[1][4] Founded in 2017 (with some sources noting 2018), the company is based in New York at 250 Hudson St and has filed three patents in cryobiology, cryogenics, and fertility medicine, reflecting embryologist-led innovation.[1][2] Early traction included FDA clearance for its automated platforms—like the high-volume storage robot, CryoBeacon for RFID-linked tracking, and CryoLink workstation—enabling digital inventory conversion and 70% space savings by replacing multiple dewars.[1][2][4] Pivotal recognition came with Fast Company's top biotech honor in 2022, fueling U.S. clinic partnerships and international entry.[1][2]
TMRW rides the surge in assisted reproductive technologies, where advances have boosted egg/embryo freezing amid growing fertility treatment demand, straining manual lab systems.[1][4] Timing aligns with biotech automation trends, digitizing high-stakes cryostorage akin to supply chain tech in other sectors, while market forces like clinic scaling and error-risk aversion favor its solutions—especially post high-profile IVF incidents.[1][2][5] It influences the ecosystem by setting new care standards, enabling clinics to optimize workflows, expand capacity, and deliver patient peace of mind, with U.S. adoption paving the way for global scalability in a fragmented fertility market.[1][4]
TMRW Life Sciences is poised to dominate IVF automation as fertility demand escalates, with next steps including deeper European/UK penetration, biorepository expansions, and potential new platforms beyond storage (e.g., full lab workflows).[1][2][4] Trends like AI-enhanced monitoring, regulatory pushes for safety, and personalized medicine will amplify its edge, potentially evolving it into a comprehensive fertitech leader influencing clinic standards worldwide. This positions TMRW to safeguard more "precious cells for life," transforming fertility tech from risky manual ops to reliable, scalable precision.[1][4]
TMRW Life Sciences has raised $138.0M across 2 funding rounds. Most recently, it raised $28.0M Series D in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $28.0M Series D | Vasudev Bailey, Highland Capital Partners, Hoxton Ventures, Pieter Kemps, Questa Capital, Radical Ventures, The House Fund, What If Ventures, Michael Baum | |
| Jul 1, 2021 | $110.0M Series C | AngelList, Vasudev Bailey, Cyberstarts VC, DST Global, Founders Fund, Fuel Ventures, GreaterGoodSociety, Greycroft, Hetz Ventures, Highland Capital Partners, Hoxton Ventures, Innovation Endeavors, Insight Partners, Mars Growth Capital, Pieter Kemps, Presight Capital, Questa Capital, Radical Ventures, Section 32, Sequoia Capital, The House Fund, Transformation Capital, Valar Ventures, What If Ventures, Xfund, Abhinav Asthana, Ben Bernstein, Danny Hadar, Erik Podzuweit, Florian Prucker, Mato Peric, Michael Baum, Oliver Jung, Patrick S. Chung, Philippe Teixeira da Mota, Richard Branson, Tushar Ahluwalia, Yevgeny Dibrov |